^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    nelistotug (GSK6097608)

    i
    Other names: GSK6097608, GSK’608, GSK-608, GSK-6097608, GSK 608, GSK 6097608
    Associations

    News

    Trials
    Company:
    23andMe, GSK
    Drug class:
    CD96 inhibitor
    Associations

    News

    Trials
    3ms
    First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=158, Recruiting, GlaxoSmithKline | Trial completion date: Sep 2028 --> Aug 2027 | Trial primary completion date: Sep 2028 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608) • risvutatug rezetecan (GSK5764227)
    4ms
    Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=107, Active, not recruiting, GlaxoSmithKline | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    4ms
    A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 (clinicaltrials.gov)
    P2, N=316, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    6ms
    GALAXIES LUNG-201: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer (clinicaltrials.gov)
    P2, N=351, Active, not recruiting, GlaxoSmithKline | Trial completion date: Oct 2028 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    9ms
    GALAXIES LUNG-201: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer (clinicaltrials.gov)
    P2, N=351, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    10ms
    Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3 (clinicaltrials.gov)
    P2, N=62, Completed, GlaxoSmithKline
    New P2 trial
    |
    Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    11ms
    Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=107, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting | N=244 --> 107 | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    1year
    Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=176, Completed, GlaxoSmithKline | Recruiting --> Completed | Trial completion date: Jul 2025 --> May 2024 | Trial primary completion date: Jul 2025 --> May 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Yervoy (ipilimumab) • docetaxel • Jemperli (dostarlimab-gxly) • feladilimab (GSK3359609) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    over1year
    First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=141, Recruiting, GlaxoSmithKline | Trial completion date: Oct 2026 --> Sep 2028 | Trial primary completion date: Oct 2026 --> Sep 2028
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608) • risvutatug rezetecan (GSK5764227)
    over1year
    GALAXIES LUNG-201: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer (clinicaltrials.gov)
    P2, N=340, Recruiting, GlaxoSmithKline | Trial completion date: Jan 2028 --> Oct 2028 | Trial primary completion date: Jan 2025 --> Oct 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    over1year
    A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 (clinicaltrials.gov)
    P2, N=360, Recruiting, GlaxoSmithKline | Trial completion date: Aug 2027 --> May 2027 | Trial primary completion date: Sep 2025 --> May 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    2years
    Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P2, N=360, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting | Trial completion date: Mar 2027 --> Aug 2027 | Trial primary completion date: Mar 2027 --> Sep 2025
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Jemperli (dostarlimab-gxly) • nelistotug (GSK6097608)